During the past decade, UCLA Department of Neurology conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 8 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCLA Department of Neurology" #1 sponsor was "Horizon Pharma Ireland, Ltd., Dublin Ireland" with 3 trials, followed by "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 3 trials sponsored, "University of California, Los Angeles" with 3 trials sponsored, "Pfizer" with 2 trials sponsored and "Alzheimer's Disease Cooperative Study (ADCS)" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA Department of Neurology" #1 collaborator was "Friedreich's Ataxia Research Alliance" with 3 trials as a collaborator, "National Institute on Aging (NIA)" with 3 trials as a collaborator, "Pfizer" with 3 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator and "DSM Nutritional Products, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "UCLA Department of Neurology" are "Alzheimer's Disease" (5 trials), "Friedreich's Ataxia" (3 trials), "Huntington's Disease" (3 trials), "Alzheimer Disease" (1 trials) and "Alzheimer Disease, Early Onset" (1 trials). Many other conditions were trialed in "UCLA Department of Neurology" in a lesser frequency.

Most popular intervention types in "UCLA Department of Neurology" are "Drug" (13 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Bapineuzumab 0.5 mg/kg" (2 trials), "Bapineuzumab 1.0 m/kg" (2 trials), "Interferon γ-1b" (2 trials) and "Placebo Control" (2 trials). Other intervention names were less common.

The vast majority of trials in "UCLA Department of Neurology" are 14 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "UCLA Department of Neurology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in UCLA Department of Neurology, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA Department of Neurology, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".